Patients with Clostridioides difficile infections who also have metabolic dysfunction–associated steatohepatitis are at increased risk for death and other severe complications, according to a retrospective study drawn from the National Inpatient Sample.
The investigators, from Rutgers-Robert Wood Johnson Medical School, in New Brunswick, N.J., noted that there is evidence that metabolic-dysfunction–associated steatotic liver disease (MASLD) or metabolic-dysfunction–associated